FOR IMMEDIATE RELEASE
Medidata Rave Selected by Wyeth Pharmaceuticals
for Enterprise-Wide EDC Deployment
Industry-Leading Global Pharmaceutical Company Looks to Medidata Solutions to
Improve Clinical Development Process and Further Build R&D Pipeline
NEW YORK, NY – October 23, 2007 – Medidata Solutions, a global provider of electronic clinical data capture (EDC), management and reporting solutions, today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has selected Medidata Rave® as its enterprise-wide EDC solution. This strategic partnership with Medidata will further enhance Wyeth’s clinical operations and build upon successful EDC programs already in place.
“The deployment of EDC technology has been an extremely important initiative at Wyeth—in the past 11 months, we have increased the rate of EDC usage in trials to more than 90 percent,” said Ira Spector, Vice President of Clinical Development Operations at Wyeth Research. “The implementation of Medidata Rave is critical to our ability to further increase and maximize our EDC usage while continuing to improve the overall productivity of our R&D organization.”
One of the top 10 largest pharmaceutical companies in the world, Wyeth plans to conduct several hundred global studies using Medidata Rave during a seven-year term, with the first trial beginning in the first quarter of 2008.
In order to select its next-generation EDC solution that would support the increasing volume of its R&D pipeline, Wyeth conducted an evaluation of vendors in 2006. Wyeth narrowed its selection to two leading companies and chose Medidata Solutions for Rave’s breadth of functionality as well as the company’s depth of experience in the marketplace and overall corporate culture. Wyeth anticipates Medidata Rave will bring higher productivity and increased efficiencies and also offer a range of ease-of-use capabilities to the investigators that are of such critical importance to the clinical trial process.
“We are extremely pleased that Wyeth has selected Medidata Rave as its enterprise-wide EDC solution and are committed to collaborating with the company to advance its clinical processes,” said Tarek Sherif, CEO at Medidata Solutions. “Wyeth’s strategic decision to move to Medidata Rave as its EDC standard is further proof that our industryleading technology is the system of choice for life sciences companies of all sizes. Over the past two years, we have seen the industry increasingly move to global, enterprisewide implementations of Medidata Rave, reflecting the versatility and scalability of our product and services.”
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data—the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market—on six continents and in more than 80 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com